Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 8,158 matching trials from the live ClinicalTrials.gov search.
Filters: Phoenix, Arizona Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

NCT01901185
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Etanercept / Autoinjector A
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

NCT01104025
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
ATG, rabbit, Etoposide, Methotrexate, hydrocortisone, Dexamethasone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

AcQBlate Force Sensing Ablation System US IDE for Atrial Flutter (AcQForce Flutter)

NCT04658940
View directory record Official record
Conditions
Typical Atrial Flutter
Interventions
AcQBlate® Force Sensing Ablation System
Device
Lead sponsor
Acutus Medical
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Concord, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 2:15 AM EDT
Terminated Phase 3 Interventional Results available

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

NCT03892889
View directory record Official record
Conditions
Schizophrenia
Interventions
Abilify MyCite®
Combination Product
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
68
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 30, 2026, 2:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Standard Adjuvant Endocrine Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
162
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Early Phase 1 Interventional

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

NCT02207010
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
AZD1775
Biological
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 30, 2026, 2:15 AM EDT
Active, not recruiting Not applicable Interventional

Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

NCT04090424
View directory record Official record
Conditions
Burns
Interventions
NovoSorb BTM, Standard of Care
Device · Procedure
Lead sponsor
PolyNovo Biomaterials Pty Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

NCT00197080
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Ropinirole Extended Release (XR)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Alabaster, Alabama • Jasper, Alabama • Mesa, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

NCT00312780
View directory record Official record
Conditions
Albuminuria, Diabetic Nephropathy
Interventions
XL784
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 30, 2026, 2:15 AM EDT
Terminated Phase 1 Interventional

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00003380
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 30, 2026, 2:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed No phase listed Observational

Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients

NCT03107689
View directory record Official record
Conditions
Overdose
Interventions
administration of intravenous lipid emulsion
Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 30, 2026, 2:15 AM EDT
Active, not recruiting Not applicable Interventional

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

NCT05896189
View directory record Official record
Conditions
Breast Cancer, Cognitive Impairments
Interventions
Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 100 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
673
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 483 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome

NCT02738450
View directory record Official record
Conditions
Down Syndrome
Interventions
ACI-24 low dose, ACI-24 high dose, Placebo
Biological
Lead sponsor
AC Immune SA
Industry
Eligibility
25 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • La Jolla, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Davunetide, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
41 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

P3 Long Term Safety Study of Once Daily SB204 in Acne

NCT02798120
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

NCT07700979
View directory record Official record
Conditions
Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions
Cadonilimab, CAPOX regimen, Nivolumab, Placebo
Drug
Lead sponsor
Akeso
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

NCT00036062
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury
Interventions
Sivelestat
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

NCT00375193
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Amrubicin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
44
States / cities
Phoenix, Arizona • Lone Tree, Colorado • Ocala, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 2 Interventional

SB-480848 In Subjects With Coronary Heart Disease

NCT00269048
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB-480848, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting No phase listed Observational

Phagenyx® Registry Study

NCT06866418
View directory record Official record
Conditions
Dysphagia
Interventions
1. Phagenyx® System Group Patients
Device
Lead sponsor
Phagenesis Ltd.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
3
States / cities
Phoenix, Arizona • Neptune City, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT01095796
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, Atripla, Stribild Placebo, Atripla Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 30, 2026, 2:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

NCT05848687
View directory record Official record
Conditions
Lymphoblastic Leukemia
Interventions
Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 1 Year
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 2:15 AM EDT